The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikitina A.J.

Russian Medical Academy of continuous Professional Education

Melnikova N.V.

Russian Medical Academy for Continuous Professional Education

Moshetova L.K.

Russian Medical Academy of Continuing Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Visual disturbances in Parkinson’s disease

Authors:

Nikitina A.J., Melnikova N.V., Moshetova L.K., Levin O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11‑2): 5‑11

DOI: 10.17116/jnevro20221221125

Read: 6240 times

Download PDF (RU)
Contact the author
Table of contents

VISUAL DISTURBANCES IN PARKINSON’S DISEASE
VISUAL DISTURBANCES IN PARKINSON’S DISEASE

To cite this article:

Nikitina AJ, Melnikova NV, Moshetova LK, Levin OS. Visual disturbances in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11‑2):5‑11. (In Russ.)
https://doi.org/10.17116/jnevro20221221125

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
The effect of bila­teral subthalamic nucleus deep brain stimulation on gait and bala­nce in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):94-101
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Abstract:

Parkinson’s disease (PD) is a slowly progressive neurodegenerative disease, the main symptoms of which are motor impairments (bradykinesia, rigidity, tremor and postural instability). However, the longer this disease is studied, the more new (non-motor) manifestations of the disease are detected. The article discusses visual disturbances that occur in patients with PD, the underlying pathogenetic mechanisms and methods of their treatment.

Keywords:

Parkinson’s disease
neurodegenerative disease
dry eye disease
retina
visual disturbances

Authors:

Nikitina A.J.

Russian Medical Academy of continuous Professional Education

Melnikova N.V.

Russian Medical Academy for Continuous Professional Education

Moshetova L.K.

Russian Medical Academy of Continuing Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Received:

21.06.2022

Accepted:

22.06.2022

Close metadata

References:

  1. Borm CDJM, Werkmann M, Graaf D, et al. Undetected ophthalmological disorders in Parkinson’s disease. Journal of Neurology. 2022;1-12.  https://doi.org/10.1007/s00415-022-11014-0
  2. Somov EE, Obodov VA. Lacrimal dysfunction syndromes. SPb: Chelovek; 2011. (In Russ).
  3. Edman MC, Janga SR, Kakan SS, et al. Tears-moretothem than meets the eye: why tears are a good source of biomarkers in Parkinson’s disease. Biomarkers in Medicine. 2020;14(2):151-163.  https://doi.org/10.2217/bmm-2019-0364
  4. Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiology of Disease. 2019;134:104700. https://doi.org/10.1016/j.nbd.2019.104700
  5. Ulusoy EK, Ulusoy DM. Evaluation of corneal sublayers thickness and corneal parameters in patients with Parkinson’s disease. International Journal of Neuroscience. 2021;131(10):939-945.  https://doi.org/10.1080/00207454.2020.1761353
  6. Roda M, Ciavarella C, Giannaccare G, Versura P. Biomarkers in tears and ocular surface: a window for neurodegenerative diseases. Eye & Contact Lens. 2020;46:S129-S134. https://doi.org/10.1097/ICL.0000000000000663
  7. Ekker MS, Janssen S, Seppi K, et al. Ocular and visual disorders in Parkinson’s disease: common but frequently overlooked. Parkinsonism & Related Disorders. 2017;40:1-10.  https://doi.org/10.1016/j.parkreldis.2017.02.014
  8. Wang MTM, Tien L, Han A, et al. Impact of blinking on ocular surface and tear film parameters. The Ocular Surface. 2020;16(4):424-429.  https://doi.org/10.1016/j.jtos.2018.06.001
  9. Avetisova SE, Egorova EA, Moshetova LK, et al. Ophthalmology. National Guidelines. M.: Geotar-Media; 2019. (In Russ).
  10. Brzhevsky VV. Diagnosis and treatment of dry eye syndrome. SPb: Sankt-Peterburgskaya gos. pediatr. med. akademiya; 1998. (In Russ).
  11. Savitt J, Aouchiche R. Management of visual dysfunction in patients with Parkinson’s disease. Journal of Parkinson’s Disease. 2020;10(s1):S49-S56.  https://doi.org/10.3233/JPD-202103
  12. Savitt J, Mathews M. Treatment of Visual Disorders in Parkinson Disease. Current Treatment Options in Neurology. 2018;20(8):30.  https://doi.org/10.1007/s11940-018-0519-0
  13. Rouen PA, White ML. Dry eye disease: prevalence, assessment, and management. Home Healthcare Now. 2018;36(2):74-83.  https://doi.org/10.1097/NHH.0000000000000652
  14. Borm CDJM, Smilowska K, de Vries NM, et al. The Neuro-Ophthalmological Assessment in Parkinson’s Disease. Journal of Parkinson’s Disease. 2019;9(2):427-435.  https://doi.org/10.3233/JPD-181523
  15. Levin OS, Fedorova NV. Bolezn’ Parkinsona. 5-e izd. M.: MEDpress-inform; 2015. (In Russ).
  16. Veys L, Vandenabeele M, Ortuno-Lizaran I, et al. Retinal alpha-synuclein deposits in Parkinson’s disease patients and animal models. Acta Neuropathological. 2019;137(3):379-395.  https://doi.org/10.1007/s00401-018-01956-z
  17. Ortuno-Lizaran I, Beach TG, Serrano GE, et al. Phosphorylated α-synuclein in the retina is a biomarker of Parkinson’s disease pathology severity. Movement Disorders. 2018;33(8):1315-1324. https://doi.org/10.1002/mds.27392
  18. Bodis-Wollner I, Kozlowsi PB, Glazman S, Miri S. α-synuclein in the inner retina in Parkinson disease. Annals of Neurology. 2014;75(6):964-966.  https://doi.org/10.1002/ana.24182
  19. Beach TG, Carew J, Serrano G, et al, Arizona Parkinson’s Disease Consortium. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neuroscience Letters. 2014;571:34-38.  https://doi.org/10.1016/j.neulet.2014.04.027
  20. Schapansky J, Nardozzi JD, LaVoie MJ. The complex relationships between microglia, α-synuclein and LRRK2 in Parkinson’s disease. Neuroscience. 2015;302:74-88.  https://doi.org/10.1016/j.neuroscience.2014.09.049
  21. Scheiblich H, Dansokho C, Mercan D, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184(20):5089-5106.e21.  https://doi.org/10.1016/j.cell.2021.09.007
  22. Ramirez AI, de Hoz R, Salobrar-Gracia E, et al. The role of microglia in retinal neurodegeneration: Alzgeimer`s disease, Parkinson, and glaucoma. Frontiers in Aging Neuroscience. 2017;9:214.  https://doi.org/10.3389/fnagi.2017.00214
  23. Miri S, Glazman S, Mylin L, Bodis-Wollner I. A combination of retinal morphology and visual electrophysiology testing increases diagnostic yield in Parkinson’s disease. Parkinsonism & Related Disorders. 2016;22:S134-S137. https://doi.org/10.1016/j.parkreldis.2015.09.015
  24. Perez-Fernandez V, Milosavljevic N, Allen AE, et al. Rod photoreceptor activation alone defines the release of dopamine in the retina. Current Biology. 2019;29(5):763-774.e5.  https://doi.org/10.1016/j.cub.2019.01.042
  25. Jackson CR, Ruan GX, Aseem F, et al. Retinal dopamine mediates multiple dimensions of light-adapted vision. Journal of Neuroscience. 2012;32(27): 9359-9368. https://doi.org/10.1523/JNEUROSCI.0711-12.2012
  26. Marrocco E, Esposito F, Tarallo V, et al. α-synuclein in the retina leads to degeneration of dopamine amacrine cells impairing vision. bioRxiv. 2019;760603. https://doi.org/10.1101/760603
  27. La Morgia C, Ross-Cisneros FN, Sadun AA, Carelli V. Retinal ganglion cells and circadian rhythms in Alzheimer’s disease, Parkinson’s disease and beyond. Frontiers in Neurology. 2017;8:162.  https://doi.org/10.3389/fneur.2017.00162
  28. Vuong HE, Hardi CN, Barnes S, Brecha NC. Parallel inhibition of dopamine amacrine cells and intrinsically photosensitive retinal ganglion cells in a non-image-forming visual circuit of mouse retina. Journal of Neuroscience. 2015;35(48):15955-15970. https://doi.org/10.1523/JNEUROSCI.3382-15.2015
  29. Ortuno-Lizaran I, Esquiva G, Beach TG, et al. Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease. Acta Neuropathologica Communications. 2018;6(1):1-10.  https://doi.org/10.1186/s40478-018-0596-z
  30. Munteanu T, Noronha KJ, Leung AC, et al. Light-dependent pathways for dopaminergic amacrine cells development and function. eLife. 2018;7:e39866. https://doi.org/10.7554/eLife.39866
  31. Miri S, Glazman S, Bodis-Wollner I. OCT and Parkinson’s disease. OCT in Central Nervous System Diseases. 2016;105-121.  https://doi.org/10.1007/978-3-319-24085-5_6
  32. Chrysou A, Jansonius NM, van Laar T. Retinal layers in Parkinson’s disease: A meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism & Related Disorders. 2019;64:40-49.  https://doi.org/10.1016/j.parkreldis.2019.04.023
  33. Pilat A, McLean RJ, Proudlock FA, et al. In vivo Morphology of Optic Nerve and Retina in Patients with Parkinson’s disease. Investigative Ophthalmology and Visual Science. 2016;57(10):4420-4427. https://doi.org/10.1167/iovs.16-20020
  34. Egorova EA. Glaukoma. National Guidelines. M.: Geotar-media; 2013. (In Russ).
  35. Kaur M, Saxena R, Singh D, et al. Correlation between structural and functional retinal changes in Parkinson disease. Journal of Neuro-Ophthalmology. 2015;35(3):254-258.  https://doi.org/10.1097/WNO.0000000000000240
  36. Ahn J, Lee JY, Kim TW, et al. Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. Neurology. 2018;91(11):e1003-e1012. https://doi.org/10.1212/WNL.0000000000006157
  37. Lee JJ, Shin NY, Lee Y, et al. Optic nerve integrity as a visuospatial cognitive predictor in Parkinson’s disease. Parkinsonism & Related Disorders. 2016;31:41-45.  https://doi.org/10.1016/j.parkreldis.2016.06.020
  38. Lee JY, Ahn J, Yoon EJ, et al. Macular ganglion-cell-complex layer thinning and optic nerve integrity in drug-naïve Parkinson’s disease. Journal of Neural Transmission. 2019;126(12):1695-1699. https://doi.org/10.1007/s00702-019-02097-7
  39. Arrigo A, Calamuneri A, Milardi D, et al. Visual system involvement in patients with newly diagnosed Parkinson disease. Radiology. 2017;285(3):885-895.  https://doi.org/10.1148/radiol.2017161732
  40. Ridder A, Muller MLTM, Kotagal V, et al. Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. Parkinsonism & Related Disorders. 2017;34:15-19.  https://doi.org/10.1016/j.parkreldis.2016.10.006
  41. Anang JBM, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson’s disease: A prospective cohort study. Neurology. 2014;83(14):1253-1260. https://doi.org/10.1212/WNL.0000000000000842
  42. Murueta‐Goyena A, Del Pino R, Galdós M, et al. Retinal thickness predicts the risk of cognitive decline in Parkinson disease. Annals of Neurology. 2021; 89(1):165-176.  https://doi.org/10.1002/ana.25944
  43. Leyland L-A, Bremner FD, Mahmood R, et al. Visual tests predict dementia risk in Parkinson disease. Neurology: Clinical Practice. 2020;10(1):29-39.  https://doi.org/10.1212/CPJ.0000000000000719
  44. Weil RS, Schrag AE, Warren JD, et al. Visual dysfunction in Parkinson’s disease. Brain. 2016;139(11):2827-2843. https://doi.org/10.1093/brain/aww175
  45. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson’s disease and incident dementia: longitudinal study. Journal of Nuclear Medicine. 2011;52(6):858-855.  https://doi.org/10.2967/jnumed.111.089946
  46. Lenka A, Jhunjhunwala KR, Saini J, Pal PK. Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: A critical review. Parkinsonism & Related Disorders. 2015;21(7):683-691.  https://doi.org/10.1016/j.parkreldis.2015.04.005
  47. Barrell K, Bureau B, Turcano P, et al. High-order visual processing, visual symptoms, and visual hallucinations: A possible symptomatic progression of Parkinson’s disease. Frontiers in Neurology. 2018;9.  https://doi.org/10.3389/fneur.2018.00999
  48. O`Callaghan C, Hall JM, Tomassini A, et al. Visual Hallucinations are characterized by impaired sensory evidence accumulation: insights from hierarchical drift diffusion modeling in Parkinson’s disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimagining. 2017;2(8):680-688.  https://doi.org/10.1016/j.bpsc.2017.04.007
  49. Pagonabarraga J, Martinez-Horta S, de Bobadilla RF, et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Movement Disorders. 2016;31(1):45-52.  https://doi.org/10.1002/mds.26432
  50. Lenka A, Pagonabarraga J, Pal PK, et al. Minor hallucinations in Parkinson’s disease: A subtle symptom with major clinical implications. Neurology. 2019;93(6):259-266.  https://doi.org/10.1212/WNL.0000000000007913
  51. Lee W-W, Yoon EJ, Lee J-Y, et al. Visual hallucinations and pattern of brain degeneration in Parkinson’s disease. Neurodegenerative Diseases. 2017; 17(2-3):62-72.  https://doi.org/10.1159/000448517
  52. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers. 2021;7(1):1-21.  https://doi.org/10.1038/s41572-021-00280-3
  53. Hermanowicz N, Edwards K. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21(10 Suppl): s199-s206.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.